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The coronavirus disease 19 (COVID-19) pandemic has seen the development and deployment of vaccines at an unprecedented speed and scale. Several vaccines including 
ChAdOx1nCoV-19 and BNT162b2 are approved for use in multiple 
countries and these have been shown to reduce COVID-19 infec-
tions, transmissions, hospitalizations and deaths in randomized 
controlled trials and real-world effectiveness studies1–6. However, 
the clinical trials were underpowered to detect rare adverse events3,4 
that are important for ongoing risk–benefit evaluations of these 
vaccines and for informing post-vaccination clinical practice. 
Therefore, the identification of such rare adverse events is now a 
global scientific priority.
The increased risk of cerebral venous sinus thrombosis follow-
ing the ChAdOx1nCoV-19 vaccine is an example of a rare adverse 
neurological event7,8. These findings have prompted the United 
Kingdom, several European countries and two Canadian prov-
inces to limit the use of the ChAdOx1nCoV-19 vaccine or restrict 
its use pending further risk–benefit analysis in those at low risk 
of severe outcomes from infection. Furthermore, two cases of 
transverse myelitis were identified in the treatment arm during 
ChAdOx1nCoV-19 clinical trials3. These cases triggered two tem-
porary study pauses, including careful regulatory review by the UK’s 
Medicines and Healthcare Products Regulatory Agency (MHRA). 
One case of transverse myelitis was considered to be possibly caus-
ally related to the vaccine, and an association of rare neuroinflam-
matory side-effects with ChAdOx1nCoV-19 could not be ruled out.
Since the start of large-scale vaccine programs across the world, 
additional case reports have linked other neurological adverse 
events to COVID-19 vaccination, including Guillain–Barré syn-
drome9–11. Furthermore, surveillance studies have found a pos-
sible link between severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) infection and neurological events, including 
Guillain–Barré syndrome and myelitis12,13. However, case reports 
and surveillance studies are limited by small numbers, as well as 
potential selection and recording biases. Therefore, detailed assess-
ments of potential neurological adverse events associated with 
COVID-19 vaccines and infection are urgently needed.
The English National Immunisation (NIMS) Database of 
COVID-19 vaccination includes data on vaccine type, date and 
doses for all people vaccinated in England. We linked NIMS, at 
the individual patient level, to national data for mortality, hospital 
admissions and SARS-CoV-2 infection data to examine the asso-
ciations between the first dose of ChAdOx1nCoV-19 or BNT162b2 
vaccines and neurological complications: acute central nervous 
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Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to reg-
ulatory, clinical and public health concerns. We undertook a self-controlled case series study to investigate hospital admis-
sions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 (n = 20,417,752) or BNT162b2 
(n = 12,134,782), and after a SARS-CoV-2-positive test (n = 2,005,280). There was an increased risk of Guillain–Barré syn-
drome (incidence rate ratio (IRR), 2.90; 95% confidence interval (CI): 2.15–3.92 at 15–21 days after vaccination) and Bell’s 
palsy (IRR, 1.29; 95% CI: 1.08–1.56 at 15–21 days) with ChAdOx1nCoV-19. There was an increased risk of hemorrhagic stroke 
(IRR, 1.38; 95% CI: 1.12–1.71 at 15–21 days) with BNT162b2. An independent Scottish cohort provided further support for the 
association between ChAdOx1nCoV and Guillain–Barré syndrome (IRR, 2.32; 95% CI: 1.08–5.02 at 1–28 days). There was a 
substantially higher risk of all neurological outcomes in the 28 days after a positive SARS-CoV-2 test including Guillain–Barré 
syndrome (IRR, 5.25; 95% CI: 3.00–9.18). Overall, we estimated 38 excess cases of Guillain–Barré syndrome per 10 million 
people receiving ChAdOx1nCoV-19 and 145 excess cases per 10 million people after a positive SARS-CoV-2 test. In summary, 
although we find an increased risk of neurological complications in those who received COVID-19 vaccines, the risk of these 
complications is greater following a positive SARS-CoV-2 test.
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system (CNS) demyelinating events, encephalitis meningitis and 
myelitis, Guillain–Barré syndrome, Bell’s palsy, myasthenic disor-
ders, hemorrhagic stroke and subarachnoid hemorrhage. We use 
the same population to investigate the associations between a posi-
tive SARS-CoV-2 test as a secondary exposure and the same neu-
rological conditions. Incidence rate ratios (IRRs), that is, the rates 
of hospital admission or death from each neurological outcome in 
the risk period after vaccination or after a positive test relative to 
the baseline period, were estimated using the self-controlled case 
series (SCCS) methodology (Fig. 2)14,15. A relative incidence greater 
than 1 indicates an increased risk after vaccination or a SARS-CoV-
2-positive test. We also carried out an independent replication of the 
risk of neurological outcomes in a national cohort from Scotland 
using the SCCS design.
Results
Overall, 32,552,534 people received their first dose of COVID19 
vaccine (ChAdOx1nCoV-19, n = 20,417,752; BNT162b2, 
n = 12,134,782) in England between 1 December 2020 and 31 May 
2021. In the population of vaccinated people, 2,005,280 (~6%) had 
a SARS-CoV-2-positive test. Of those with a positive test, 1,838,628 
(~91%) had their SARS-CoV-2 test prior to vaccination. The base-
line characteristics of the study population are listed in Table 1.
The results for the investigated neurological outcomes follow-
ing each exposure (ChAdOx1nCoV-19, BNT162b2 and positive 
SARS-CoV-2 test) are given for pre-specified time periods: 0, 1–7, 
8–14, 15–21 and 22–28 days, as well as collectively for the 1–28 day 
period. The baseline characteristics of people who had these neuro-
logical outcomes are listed in Table 2. The IRRs for each outcome 
Table 1 | Baseline demographic characteristics of people receiving either ChAdOx1nCoV-19 or BNt162b2 vaccines or testing positive 
to SARS-CoV-2 virus (in those vaccinated with either vaccine), in england between 1 December 2020 and 31 May 2021
ChAdOx1nCoV-19 vaccine BNt162b2 mRNA vaccine Positive SARS-CoV-2 test (in those 
vaccinated)
% (n) % (n) % (n)
Total number of people 20,417,752 12,134,782 2,005,280
Sex
 Female 49.7 (10,150,568) 54.5 (6,608,730) 55.5 (1,113,100)
 Male 45.3 (9,240,726) 41.0 (4,978,327) 40.6 (814,383)
 Sex not recorded 5.0 (1,026,458) 4.5 (547,725) 3.9 (77,797)
Age groups (years)
 Mean (s.d.) 55.1 (14.8) 55.9 (20.1) 50.1 (16.9)
 16–29 5.2 (1,063,302) 8.7 (1,061,130) 11.3 (226,312)
 30–39 7.9 (1,610,998) 21.4 (2,598,709) 17.1 (342,943)
 40–49 21.8 (4,442,963) 11.5 (1,399,336) 21.9 (438,788)
 50–59 27.4 (5,593,753) 12.5 (1,521,131) 23.9 (479,082)
 60–69 19.8 (4,042,273) 14.1 (1,714,392) 12.9 (259,429)
 70–79 13.7 (2,803,106) 16.0 (1,942,863) 6.4 (128,302)
 80–89 3.2 (646,397) 13.4 (1,620,062) 4.5 (90,947)
 90+ 1.1 (214,960) 2.3 (277,159) 2.0 (39,477)
ethnicity
 White 72.4 (14,777,834) 74.1 (8,986,385) 70.0 (1,402,843)
 Indian 2.2 (448,696) 2.7 (324,499) 4.0 (80,762)
 Pakistani 1.3 (274,143) 1.3 (155,524) 3.0 (61,018)
 Bangladeshi 0.6 (117,396) 0.4 (53,690) 1.1 (22,900)
 Other Asian 1.0 (207,130) 1.2 (145,342) 1.8 (35,373)
 Black Caribbean 0.6 (124,735) 0.5 (61,242) 0.7 (13,789)
 Black African 1.1 (228,758) 1.0 (121,497) 1.6 (32,185)
 Chinese 0.4 (75,432) 0.4 (45,604) 0.2 (4,374)
 Other ethnic group 1.9 (387,650) 1.9 (231,506) 2.6 (51,763)
 Ethnicity not recorded 18.5 (3,775,978) 16.6 (2,009,493) 15.0 (300,273)
Neurological history
Acute CNS demyelinating events <0.1 (3,628) <0.1 (2,028) <0.1 (463)
 Prior encephalitis, meningitis and myelitis <0.1 (4,322) <0.1 (2,431) <0.1 (855)
 Prior Guillain–Barré syndrome <0.1 (1,855) <0.1 (1,226) <0.1 (294)
 Prior Bell’s palsy <0.1 (9,275) 0.1 (6,200) 0.1 (1,396)
 Prior myasthenic disorder <0.1 (3,129) <0.1 (2,609) <0.1 (461)
 Prior hemorrhagic stroke <0.1 (6,517) <0.1 (4,064) 0.1 (1,318)
 Prior subarachnoid hemorrhage <0.1 (5,350) <0.1 (2,776) <0.1 (822)
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in the risk periods immediately before and after each exposure are 
given in Table 3 and Fig. 1.
Neurological outcomes. Acute CNS demyelinating events. A total 
of 1,105 people had a hospital admission with an acute CNS demy-
elinating event. Of these, 131 (11.9%) had a positive SARS-CoV-2 
test including 121 (10.9%) who had a positive test prior to vacci-
nation. There were fewer than five deaths overall. There was no 
association between the ChAdOx1nCoV-19 or BNT162b2 vacci-
nation and admission with an acute CNS demyelinating event in 
any of the pre-defined 7 day risk periods. There was an increased 
risk of hospital admission or death for acute CNS demyelinating 
events on the day of a positive SARS-CoV-2 test (IRR, 19.34; 95% 
CI: 8.63–43.38), and 1–7 days (IRR, 3.45; 95% CI: 1.67–7.14) and 
8–14 days (IRR, 2.61; 95% CI: 1.17–5.84) after a positive test. In the 
1–28 days post-exposure period we did not observe any association 
with ChAdOx1nCoV-19 (IRR, 0.97; 95% CI: 0.78–1.22) or with 
BNT162b2 (IRR, 1.02; 95% CI: 0.75–1.40), but a possible associa-
tion with SARS-CoV-2 infection was observed (IRR, 1.67; 95% CI: 
0.93–3.00).
Encephalitis, meningitis and myelitis. Encephalitis-, meningitis- and 
myelitis-related admissions occurred in 1,285 people. Of these, 255 
(19.8%) had a SARS-CoV-2-positive test including 213 (16.6%) who 
had a positive test prior to vaccination. There were 39 deaths (in 
six of which the SARS-CoV-2 test was positive). There was a trend 
towards increased risk of encephalitis, meningitis and myelitis after 
ChAdOx1nCoV-19 vaccination (IRR, 1.32; 95% CI: 0.99–1.76 at 
8–14 days) and no association with the BNT162b2 vaccine in any 
of the 7 day risk periods. There was an increased risk of hospital 
admission or death for this outcome on the day of a SARS-CoV-
2-positive test (IRR, 38.57; 95% CI: 23.41–63.56), and 1–7 days 
(IRR, 5.71; 95% CI: 3.49–9.32) and 8–14 days (IRR, 5.63; 95% CI: 
3.64–9.15) after the positive test. In the 1–28 days post-exposure 
period we did not observe an association with ChAdOx1nCoV-19 
(IRR, 1.07; 95% CI: 0.87–1.31) or with BNT162b2 (IRR, 1.14; 95% 
CI: 0.86–1.51), but an association with SARS-CoV-2 infection was 
identified (IRR, 2.07; 95% CI: 1.78–4.11).
Guillain–Barré syndrome. Guillain–Barré syndrome-related admis-
sions occurred in 622 people. Of these, 110 (17.7%) had a positive 
SARS-CoV-2 test including 99 (15.9%) who had a positive test prior 
to vaccination. There were 11 deaths (SARS-CoV-2 test was not 
positive in any of these deaths). There was an increased risk of hos-
pital admission or death for Guillain–Barré syndrome at 15–21 days 
(IRR, 2.90; 95% CI: 2.15–3.92) and 22–28 days (IRR, 2.21; 95% 
CI: 1.59–3.09) following the first dose of ChAdOx1nCoV-19. No 
association was found with the BNT162b2 vaccine. There was an 
increased risk of Guillain–Barré syndrome following a positive 
SARS-CoV-2 test (IRR, 33.37; 95% CI: 14.21–78.36 at day 0; IRR, 
7.36; 95% CI: 3.57–15.18 at 1–7 days; IRR, 5.19; 95% CI: 2.31–11.65 
at 8–14 days; IRR, 6.89; 95% CI: 3.37–14.09 at 15–22 days; IRR, 3.51; 
95% CI: 1.44–8.57 at 22–28 days). In the 1–28 days post-vaccination 
period we found an increased risk of Guillain–Barré syndrome after 
ChAdOx1nCoV-19 vaccination (IRR, 2.04; 95% CI: 1.60–2.60) but 
not after BNT162b2 vaccination (IRR, 0.86; 95% CI: 0.54–1.36). 
Also, an increased risk of Guillain–Barré syndrome was observed in 
the 1–28 days period after a SARS-CoV-2-positive test (IRR, 5.25; 
95% CI: 3.00–9.18).
Bell’s palsy. There were 3,249 people admitted to hospital with Bell’s 
palsy. Of these, 391 (12.0%) had a positive SARS-CoV-2 test includ-
ing 334 (10.3%) who had a positive test prior to vaccination. There 


















































































































































































Time period (days since exposure)
Fig. 1 | IRRs and 95% CIs for neurological outcomes following ChAdOx1nCoV-19 vaccination, BNt162b2 vaccination and positive SARS-CoV-2 test. 
The IRRs are presented for pre-defined risk periods (0, 1–7, 8–14, 15–21 and 22–28 days) after each exposure and for the pre-risk period (28 days prior to 
exposure) and computed using a population of n = 32,553,534 vaccinated individuals. The horizontal bold line indicates an IRR of 1.
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Table 2 | Demographic characteristics of patients who had the individual outcomes in the 28 days following a COVID-19 vaccine first 
dose or SARS-CoV-2 infection in the vaccinated population in england from 1 December 2020 to 31 May 2021

























% (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n)
Total number 
of people
144 69 31 188 97 83 153 34 43
Women 57.6 (83) 65.2 (45) 54.8 (17) 58.5 (110) 56.7 (55) 45.8 (38) 45.1 (69) 44.1 (15) 46.5 (20)
Men 42.4 (61) 34.8 (24) 45.2 (14) 41.5 (78) 43.3 (42) 54.2 (45) 54.9 (84) 55.9 (19) 53.5 (23)
Age groups 
(years)
Mean (s.d.) 55.6 (15.8) 59.0 (15.3) 59.9 (18.9) 58.9 (16.9) 66.8 (19.1) 57.4 (15.5) 60.6 (13.5) 67.0 (17.1) 60.0 (15.0)
16–29 7.6 (11) * 4.3 (8) 6.2 (6) * * *
30–39 10.4 (15) * 16.1 (5) 12.8 (24) 5.2 (5) 10.8 (9) 6.5 (10) 0 *
40–49 13.2 (19) 13.0 (9) 22.6 (7) 12.2 (23) 6.2 (6) 14.5 (12) 11.1 (17) * 16.3 (7)
50–59 25.0 (36) 24.6 (17) * 18.6 (35) 15.5 (15) 25.3 (21) 24.8 (38) * 23.3 (10)
60–69 25.0 (36) 31.9 (22) 16.1 (5) 20.7 (39) 12.4 (12) 20.5 (17) 30.1 (46) 17.6 (6) 27.9 (12)
70–79 15.3 (22) 7.2 (5) 19.4 (6) 19.1 (36) 22.7 (22) 18.1 (15) 19.6 (30) 35.3 (12) 11.6 (5)
80–89 * 13.0 (9) 16.1 (5) 10.1 (19) 26.8 (26) 6.0 (5) 5.2 (8) 14.7 (5) *




10.4 (15) 8.7 (6) – 6.9 (13) 5.1 (5) – 5.2 (8) * –
After 
vaccination
* 7.2 (5) – 6.9 (13) 10.3 (10) – * * –

























% (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n)
Total number 
of people
435 250 112 99 94 67 533 385 73
Women 52.4 (228) 55.2 (138) 42.9 (48) 45.5 (45) 37.2 (35) 29.9 (20) 55.2 (294) 55.1 (212) 47.9 (35)
Men 47.6 (207) 44.8 (112) 57.1 (64) 54.5 (54) 62.8 (59) 70.1 (47) 44.8 (239) 44.9 (173) 52.1 (38)
Age groups 
(years)
Mean (s.d.) 62.6 (15.5) 70.8 (15.2) 67.1 (15.8) 67.2 (15.2) 72.7 (15.8) 66.8 (14.3) 70.9 (14.4) 77.5 (11.7) 69.0 (17.5)
16–29 2.5 (11) * * * * * 1.5 (8) * *
30–39 5.3 (23) 2.0 (5) 4.5 (5) * * * 1.1 (6) 1.3 (5) *
40–49 9.2 (40) 4.4 (11) 4.5 (5) 6.1 (6) * * 4.5 (24) 1.3 (5) 12.3 (9)
50–59 26.9 (117) 16.8 (42) 18.8 (21) 13.1 (13) 7.4 (7) 13.4 (9) 14.4 (77) 4.9 (19) 8.2 (6)
60–69 20.7 (90) 16.8 (42) 27.7 (31) 28.3 (28) 13.8 (13) 29.9 (20) 19.5 (104) 11.2 (43) 11.0 (8)
70–79 20.7 (90) 20.8 (52) 18.8 (21) 27.3 (27) 27.7 (26) 28.4 (19) 30.6 (163) 28.6 (110) 28.8 (21)
80–89 10.6 (46) 30.0 (75) 17.9 (20) 17.2 (17) 35.1 (33) 13.4 (9) 20.8 (111) 41.0 (158) 23.3 (17)




8.7 (38) 7.2 (18) – 7.1 (7) * – 8.1 (43) 3.7 (14) –
 After 
vaccination
3.2 (14) 4.4 (11) – * 11.7 (11) – 3.6 (19) 8.31 (32) –
Continued
NAtuRe MeDICINe | www.nature.com/naturemedicine
ArticlesNature MediciNe
Bell’s palsy at 15–21 days after the first dose of ChAdOx1nCoV-19 
(IRR, 1.29; 95% CI: 1.08–1.56). No association was found with the 
BNT162b2 vaccine. There was an increased risk of Bell’s palsy fol-
lowing a positive SARS-CoV-2 test (IRR, 33.23; 95% CI: 22.57–48.94 
at day 0; IRR, 5.84; 95% CI: 4.09–8.33 at 1–7 days; IRR, 2.17; 95% CI: 
1.30–3.63 at 8–14 days). In the 1–28 days post-exposure period we 
did not observe any association with ChAdOx1nCoV-19 (IRR, 1.07; 
95% CI: 0.94–1.21), BNT162b2 (IRR, 1.06; 95% CI: 0.90–1.26) or 
SARS-CoV-2 infection (IRR, 1.34; 95% CI: 0.91–1.97). In the cohort 
of patients with Bell’s palsy, a small proportion (6%) had a suspected 
concurrent diagnosis of cerebral infarction. We undertook a post-hoc 
sensitivity analysis excluding these people but the results did not 
change from the main analysis, as shown in Supplementary Table 1.
Myasthenic disorder. There were 831 hospital admissions for 
myasthenic disorder. Of these, 137 people (16.5%) had a positive 
SARS-CoV-2 test including 110 (13.2%) who had a positive test 
prior to vaccination. There were 30 deaths (in 10 of which the 
SARS-CoV-2 test was positive). There was an increased risk of hos-
pital admission or death for myasthenic disorder at 15–21 days after 
the first dose of ChAdOx1nCoV-19 (IRR, 1.57; 95% CI: 1.07–2.30). 
No association was found with the BNT162b2 vaccine. There was 
an increased risk of hospital admission or death with myasthenic 
disorder following a positive SARS-CoV-2 test (IRR, 61.32; 95% CI: 
33.43–112.50 at day 0; IRR, 13.74; 95% CI: 8.07–23.41 at 1–7 days; 
IRR, 3.98; 95% CI: 1.86–8.52 at 8–14 days; IRR, 2.81; 95% CI: 1.16–
6.79 at 22–28 days). In the 1–28 days post-exposure period we did 
not observe any association with ChAdOx1nCoV-19 (IRR, 1.23; 
95% CI: 0.94–1.62) or BNT162b2 (IRR, 1.18; 95% CI: 0.88–1.59), 
but an increased risk after a SARS-CoV-2-positive test was identi-
fied (IRR, 3.01; 95% CI: 1.70–5.36).
Hemorrhagic stroke. There were 3,503 hospital admissions due to 
hemorrhagic stroke. Of these, 483 people (13.8%) had a positive 
SARS-CoV-2 test including 392 (11.2%) who had a positive test 
prior to vaccination. There were 803 deaths (in 83 of which the 
SARS-CoV-2 test was positive). No association was found with the 
ChAdOx1nCoV-19 vaccine in any of the pre-specified time peri-
ods. There was an increased risk of hospital admission or death 
from hemorrhagic stroke at 1–7 days (IRR, 1.27; 95% CI: 1.02–1.59) 
and 15–21 days (IRR, 1.38; 95% CI: 1.12–1.71) after the first dose 
of BNT162b2. There was an increased risk of hemorrhagic stroke 
up to 7 days after a positive SARS-CoV-2 test (IRR, 12.42; 95% CI: 
7.73–19.95 at day 0; IRR, 2.01; 95% CI: 1.29–3.15 at 1–7 days). In the 
1–28 days post-vaccination period we did not observe an associa-
tion with ChAdOx1nCoV-19 (IRR, 0.91; 95% CI: 0.88–0.94), but 
a positive association with the BNT162b2 vaccine was observed 
(IRR, 1.24; 95% CI: 1.07–1.43). No association was found with 
SARS-CoV-2 infection in the 1–28 day period after a positive test 
(IRR, 0.85; 95% CI: 0.57–1.26).
Subarachnoid hemorrhage. There were 2,055 hospital admissions 
due to subarachnoid hemorrhage. Of these, 262 people (12.7%) 
had a positive SARS-CoV-2 test including 220 (10.7%) who had 
a positive test prior to vaccination. There were of 273 deaths (in 
27 of which the SARS-CoV-2 test was positive). There was no 
association between the ChAdOx1nCoV-19 and BNT162b2 vac-
cines and subarachnoid hemorrhage. There was an increased 
risk of hospital admission or death for subarachnoid hemorrhage 
on the day of a SARS-CoV-2-positive test (IRR, 24.22; 95% CI: 
14.50–40.45), and at 1–7 days (IRR, 4.17; 95% CI: 2.59–6.71) and 
8–14 days (IRR, 2.15; 95% CI: 1.16–3.99) after the positive test. In 
the 1–28 days post-exposure period we did not observe any asso-
ciation with ChAdOx1nCoV-19 (IRR, 1.01; 95% CI: 0.86–1.18) or 
with BNT162b2 (IRR, 1.05; 95% CI: 0.84–1.30), but a potentially 
increased risk after the SARS-CoV-2 infection (IRR, 1.51; 95% CI: 
0.96–2.36) was observed.
Guillain–Barré syndrome and Bell’s palsy: composite outcome. Given 
that facial weakness can be part of the spectrum of Guillain–Barré 
Subarachnoid hemorrhage
ChAdOx1nCoV-19 vaccine BNt162b2 mRNA vaccine Positive SARS-CoV-2 test
% (n) % (n) % (n)
Total number of people 308 151 68
Women 54.5 (168) 62.9 (95) 50.1 (34)
Men 45.1 (139) 36.4 (55) 50.1 (34)
Not recorded 0.3 (1) 0.7 (1) 0
Age (years)
Mean (s.d.) 63.5 (15.5) 69.7 (14.2) 64.5 (17.2)
16–29 2.6 (8) * *
30–39 3.9 (12) 3.3 (5) 8.8 (6)
40–49 9.1 (28) * 11.8 (8)
50–59 25.6 (79) 17.2 (26) 17.2 (26)
60–69 23.7 (73) 19.2 (29) 19.2 (29)
70–79 18.2 (56) 27.8 (42) 26.5 (18)
80–89 12.7 (39) 25.8 (39) 14.7 (10)
90+ 4.2 (13) * *
Positive SARS-CoV-2 test
 Before vaccination 9.1 (28) 6.6 (10)
 After vaccination 3.6 (11) 6.0 (9)
*Cells with <5 are suppressed.
Table 2 | Demographic characteristics of patients who had the individual outcomes in the 28 days following a COVID-19 vaccine first 
dose or SARS-CoV-2 infection in the vaccinated population in england from 1 December 2020 to 31 May 2021 (continued)
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syndrome, we investigated the risk of hospital admission or death 
from co-occurrence of Bell’s palsy and Guillain–Barré syndrome 
in the same individuals before and after ChAdOx1nCoV-19 and 
BNT162b2 vaccination in the study period. There were 34 patients 
admitted to hospital for both Bell’s palsy and Guillain–Barré 
syndrome. Of these patients, 27 were admitted on the same day for 
both outcomes, while seven were first admitted for Bell’s palsy and 
subsequently for Guillain–Barré syndrome. We found an increased 
risk of co-occurrence of Bell’s palsy and Guillain–Barré syndrome 
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Fig. 2 | Schematic presentation of the SCCS study design. Each patient is followed from the index date to the study end date and is censored if death 
occurred or if they had a second dose of vaccine. Risk intervals (0, 1–7, 8–14, 15–21 and 22–28 days after exposure), the pre-risk interval (the 28 days prior 
to exposure) and the baseline periods (from study start to 29 days before exposure, and from 29 days after exposure to study end) are shown.
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Table 3 | IRR and 95% CI for individual outcomes in pre-defined risk periods immediately before and after exposure to vaccination 
and before and after a positive SARS-CoV-2 test result, adjusted for calendar time from 1 December 2020 to 31 May 2021
ChAdOx1nCoV-19 vaccine BNt162b2 mRNA vaccine Positive SARS-CoV-2 test
time period events IRR (95% CI) events IRR (95% CI) events IRR (95% CI)
Acute CNS demyelinating events
 Baseline 473 1.00 244 1.00 53 1.00
 −28 to −1 days 117 0.83 (0.67–1.03) 58 0.92 (0.68–1.24) 27 2.94 (1.79–4.83)
Day 0 0 NA * 0.43 (0.16–3.05) 7 19.34 (8.63–43.38)
 1–7 days 38 1.03 (0.73–1.44) 15 0.91 (0.53–1.55) 9 3.45 (1.67–7.14)
 8–14 days 35 0.95 (0.67–1.36) 16 0.94 (0.56–1.58) 7 2.61 (1.17–5.84)
 15–21 days 38 1.04 (0.74–1.46) 16 0.92 (0.55–1.55) 6 2.05 (0.87–4.82)
 22–28 days 33 0.93 (0.65–1.33) 21 1.19 (0.75–1.89) * 0.60 (0.15–2.47)
 1–28 days 144 0.97 (0.78–1.22) 68 1.02 (0.75–1.40) * 1.67 (0.93–3.00)
Encephalitis, meningitis and myelitis
 Baseline 602 1.00 275 1.00 66 1.00
 −28 to −1 days 78 0.42 (0.33–0.54) 45 0.59 (0.42–0.82) 78 5.64 (3.91–8.13)
Day 0 * 0.46 (0.15–1.43) 0 NA 23 38.57 (23.41–63.56)
 1–7 days 52 1.15 (0.85–1.54) 22 1.02 (0.65–1.61) 24 5.71 (3.49–9.32)
 8–14 days 58 1.32 (0.99–1.76) 27 1.17 (0.77–1.77) 24 5.63 (3.46–9.15)
 15–21 days 37 0.89 (0.63–1.25) 21 0.95 (0.60–1.50) 6 1.38 (0.59–3.21)
 22–28 days 38 0.96 (0.68–1.35) 27 1.28 (0.85–1.93) 6 1.33 (0.57–3.08)
 1–28 days 185 1.07 (0.87–1.31) 97 1.14 (0.86–1.51) 60 2.70 (1.78–4.11)
Guillain–Barré syndrome
 Baseline 264 1.00 109 1.00 30 1.00
 −28 to −1 days 41 0.44 (0.31–0.63) 21 0.67 (0.41–1.10) 23 4.85 (2.67–8.82)
 Day 0 0 NA 0 NA 7 33.37 (14.21–78.36)
 1–7 days 17 0.74 (0.44–1.23) 9 0.99 (0.49–2.00) 11 7.36 (3.57–15.18)
 8–14 days 23 1.02 (0.65–1.59) 7 0.71 (0.32–1.56) 8 5.19 (2.31–11.65)
 15–21 days 65 2.90 (2.15–3.92) 9 0.91 (0.45–1.84) 11 6.89 (3.37–14.09)
 22–28 days 48 2.21 (1.59–3.09) 9 0.90 (0.45–1.82) 6 3.51 (1.44–8.57)
 1–28 days 153 2.04 (1.60–2.60) 34 0.86 (0.54–1.36) 36 5.25 (3.00–9.18)
Bell’s palsy
 Baseline 1,356 1.00 712 1.00 134 1.00
 −28 to −1 days 328 0.80 (0.70–0.91) 168 0.77 (0.65–0.92) 86 3.34 (2.49–4.48)
 Day 0 5 0.33 (0.14–0.80) * 0.36 (0.12–1.13) 35 33.23 (22.57–48.94)
 1–7 days 95 0.89 (0.72–1.11) 54 0.91 (0.69–1.21) 44 5.84 (4.09–8.33)
 8–14 days 84 0.79 (0.63–0.99) 57 0.95 (0.72–1.25) 17 2.17 (1.30–3.63)
 15–21 days 136 1.29 (1.08–1.56) 65 1.05 (0.81–1.37) 9 1.09 (0.55–2.15)
 22–28 days 115 1.13 (0.92–1.37) 71 1.17 (0.91–1.50) 7 0.80 (0.37–1.72)
 1–28 days 430 1.07 (0.94–1.21) 247 1.06 (0.90–1.26) 77 1.34 (0.91–1.97)
Myasthenic disorder
 Baseline 311 1.00 213 1.00 32 1.00
 −28 to −1 days 70 0.72 (0.54–0.96) 44 0.58 (0.41–0.83) 26 4.00 (2.30–6.96)
 Day 0 0 NA * 0.96 (0.30–3.04) 18 61.32 (33.43–112.50)
 1–7 days 17 0.70 (0.42–1.16) 18 0.83 (0.50–1.37) 29 13.74 (8.07–23.41)
 8–14 days 26 1.16 (0.76–1.77) 24 1.09 (0.70–1.71) 9 3.98 (1.86–8.52)
 15–21 days 33 1.57 (1.07–2.30) 22 1.02 (0.64–1.63) 5 2.17 (0.84–5.63)
 22–28 days 23 1.01 (0.65–1.57) 27 1.46 (0.96–2.22) 6 2.81 (1.16–6.79)
 1–28 days 99 1.23 (0.94–1.62) 91 1.18 (0.88–1.59) 49 3.01 (1.70–5.36)
Hemorrhagic stroke
Continued
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(IRR, 13.35; 95% CI: 2.48–72.92) after ChAdOx1nCoV-19 vaccina-
tion (Supplementary Table 2). In the 1–28 days post-vaccination 
period we found a positive association with the ChAdOx1nCoV-19 
vaccine (IRR, 12.66; 95% CI: 2.70–59.21) but not with the 
BNT162b2 vaccine (Supplementary Table 2). The IRRs associated 
with SARS-CoV-2 infection were not estimated due to the small 
number of events in those with a positive SARS-CoV-2 test.
National Scottish data. In Scotland 1,982,678 people received the 
first dose of ChAdOx1nCoV-19 vaccine (~10% of those in England) 
and 1,077,626 people received the first dose of BNT162b2 vaccine 
(~10% of those in England) between 1 December 2020 and 31 
May 2021. Of those vaccinated, 117,554 (~3%) had a SARS-CoV-
2-positive test, either prior to or after vaccination. The age distribu-
tion of vaccinated patients and the percentage of vaccinated patients 
having any prior conditions were similar in the Scottish and English 
populations (Supplementary Table 3a).
The association between ChAdOx1nCoV-19 and Guillain–
Barré syndrome for the 1–28 days post-vaccination period was 
replicated in Scotland (IRR, 2.31; 95% CI: 1.02–5.24), as shown in 
Supplementary Table 3b. The timing of this increased risk was con-
sistent with the results seen in England: IRR, 2.15 (95% CI: 0.63–
7.31) for 8–14 days, 4.79 (95% CI: 1.72–13.38) for 15–21 days and 
3.60 (95% CI: 1.11–11.65) for 22–28 days (Supplementary Table 3c). 
No association between BNT162b2 and hemorrhagic stroke was 
seen in Scotland (IRR, 0.65; 95% CI: 0.35–1.20) in the 1–28 days 
period after vaccination (Supplementary Table 3b). The findings for 
SARS-CoV-2 test positivity were similar to the English data, with 
an increased risk of neurological outcomes following a positive test, 
although the estimates were generally imprecise due to the smaller 
population and lower rates of infection.
Subgroup analyses by age group and sex. We tested for interac-
tions between vaccination and age group (>50 years and ≤50 years) 
and sex for the outcomes for which we observed an increased risk 
after vaccination. Supplementary Table 4a lists the results of the 
interaction tests. When interaction terms were statistically signifi-
cant, the IRR for subgroup analyses by age group or sex have been 
reported in Supplementary Table 4b. There was a significant interac-
tion (P = 0.016) between age group and risk of myasthenic disorder 
associated with the ChAdOx1nCoV-19 vaccine (IRR, 2.44; 95% CI: 
1.07–5.55 at 15–21 days) in people aged ≤50 years. The increased 
risk of hemorrhagic stroke associated with the BNT162b2 vaccine 
was significantly higher in female participants (P = 0.007): the IRR 
for hemorrhagic stroke in female participants was 1.44 (95% CI: 
1.05–1.96) at 1–7 days and 1.84 (95% CI: 1.40–2.42) at 15–21 days 
after BNT162b2 vaccination compared with 1.13 (95% CI: 0.82–
1.57) at 1–7 days and 0.98 (95% CI: 0.70–1.38) at 15–21 days in male 
participants.
Excess events due to exposures. We estimated the number of 
exposures needed for one excess event and the excess number of 
events per 10 million exposed for each outcome (Supplementary 
Table 5). For example, with ChAdOx1nCoV-19 there were 38 excess 
Guillain–Barré syndrome events per 10 million people vaccinated 
in the 1–28 days period after vaccination. For BNT1262b2, there 
were 60 extra cases of hemorrhagic stroke per 10 million people vac-
cinated in the 1–28 days period after vaccination. For SARS-CoV-2 
infection, in the 1–28 days period after a positive test there were an 
estimated 123 extra events of encephalitis meningitis and myelitis 
and 145 of Guillain–Barré syndrome per 10 million people with a 
positive test.
Associations with negative and positive control outcomes. We 
examined the associations of exposures with celiac disease as a 
negative control outcome and with anaphylaxis as a positive con-
trol outcome. We found no increased risk of celiac disease (negative 
control) across the pre-specified time periods for the vaccine expo-
sures, but a decreased risk on the day of vaccination. Anaphylaxis 
(positive control) showed the expected increased risk in the 
ChAdOx1nCoV-19 vaccine BNt162b2 mRNA vaccine Positive SARS-CoV-2 test
time period events IRR (95% CI) events IRR (95% CI) events IRR (95% CI)
 Baseline 1,456 1.00 811 1.00 173 1.00
 −28 to −1 days 232 0.47 (0.41–0.55) 86 0.36 (0.29–0.46) 163 4.73 (3.72–6.02)
 Day 0 7 0.37 (0.18–0.78) 6 0.59 (0.27–1.33) 20 12.42 (7.73–19.95)
 1–7 days 131 0.98 (0.82–1.18) 93 1.27 (1.02–1.59) 23 2.01 (1.29–3.15)
 8–14 days 141 1.06 (0.89–1.27) 89 1.18 (0.94–1.48) 14 1.19 (0.69–2.07)
 15–21 days 128 0.98 (0.81–1.18) 106 1.38 (1.12–1.71) 10 0.84 (0.44–1.61)
 22–28 days 126 1.00 (0.83–1.21) 91 1.15 (0.92–1.44) 6 0.51 (0.23–1.16)
 1–28 days 526 1.02 (0.90–1.15) 379 1.24 (1.07–1.43) 53 0.85 (0.57–1.26)
Subarachnoid hemorrhage
 Baseline 971 1.00 415 1.00 88 1.00
 −28 to −1 days 157 0.49 (0.41–0.58) 53 0.43 (0.32–0.58) 60 3.40 (2.38–4.86)
 Day 0 * 0.34 (0.13–0.91) 0 NA 19 24.22 (14.50–40.45)
 1–7 days 70 0.85 (0.66–1.10) 38 1.08 (0.77–1.52) 23 4.17 (2.59–6.71)
 8–14 days 93 1.16 (0.93–1.44) 41 1.14 (0.82–1.59) 12 2.15 (1.16–3.99)
 15–21 days 72 0.92 (0.72–1.18) 31 0.85 (0.58–1.23) 7 1.23 (0.57–2.67)
 22–28 days 69 0.94 (0.73–1.20) 41 1.16 (0.84–1.61) 7 1.19 (0.55–2.58)
 1–28 days 304 1.01 (0.86–1.18) 151 1.05 (0.84–1.30) 49 1.51 (0.96–2.36)
*Cells with <5 are suppressed. NA, not applicable.
Table 3 | IRR and 95% CI for individual outcomes in pre-defined risk periods immediately before and after exposure to vaccination 
and before and after a positive SARS-CoV-2 test result, adjusted for calendar time from 1 December 2020 to 31 May 2021 (continued)
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0–7 days after the first dose for both vaccines, but not in later peri-
ods (Supplementary Table 6).
Sensitivity analyses. We conducted a number of sensitivity analyses 
to ascertain the robustness of our results. Overall, the main findings 
were not sensitive to censoring due to death (with the exception of 
hemorrhagic stroke), removal of patients who had a second dose of 
the vaccine or adjustment for potential delays in recording. Results 
for these sensitivity analyses are shown in Supplementary Table 7a 
and Extended Data Figs. 1 and 2. We also extended the exposure risk 
period to 5 weeks, to test the suitability of our 28 day risk period and 
to avoid missing events due to lag in diagnosis. Results were similar 
to the main analysis (Supplementary Table 7b). An increased risk 
of Guillain–Barré syndrome was observed in the 29–35 days after 
ChAdOx1nCoV-19 vaccination (IRR, 1.55; 95% CI: 1.03–2.34).
We have further restricted the analyses to patients who had a 
positive SARS-CoV-2 test before vaccination. The results did not 
change from the main analysis for the SARS-CoV-2 test exposure 
(Supplementary Table 7c), suggesting that there is a higher risk 
of neurological complications after a positive SARS-CoV-2 test 
for all outcomes. The number of people infected after vaccination 
was too small to carry out any additional meaningful analyses. We 
also restricted the analyses to those who did not have a positive 
SARS-CoV-2 test. The results did not change from the main analysis 
for both vaccine exposures (Supplementary Table 7d).
Discussion
This large population-based study of more than 32 million people 
investigated the neurological adverse events associated with the 
ChAdOx1nCoV-19 and BNT162b2 vaccines as well as SARS-CoV-2 
infection. We identified several key findings that are timely and of 
high importance to the public, health policy makers and clinicians 
across the world. First, we found an increased risk of hospital admis-
sion for Guillain–Barré syndrome (15–21 days and 22–28 days), 
Bell’s palsy (15–21 days) and myasthenic disorders (15–21 days) 
in those who received the ChAdOx1nCoV-19 vaccine. Second, 
an increased risk of hospital admission for hemorrhagic stroke 
(1–7 days and 15–21 days) was observed in those who received the 
BNT162b2 vaccine. Last, we identified a much greater increase in 
the risk of neurological outcomes following a positive SARS-CoV-2 
test, such as acute CNS demyelinating events, encephalitis meningi-
tis and myelitis, Guillain–Barré syndrome, Bell’s palsy, myasthenic 
disorders, hemorrhagic stroke and subarachnoid hemorrhage. 
Apart from hemorrhagic stroke, the results were robust to sensi-
tivity analyses that assessed the assumption that outcomes did not 
influence subsequent exposures, providing credence to our results.
In those who received the ChAdOx1nCoV-19 vaccine, we esti-
mated 38 excess cases of Guillain–Barré syndrome per 10 mil-
lion exposed in the 1–28 days risk period. However, we did not 
observe an increased risk of Guillain–Barré syndrome in those 
who received the BNT162b2 vaccine. We replicated these findings 
using an independent national cohort of more than 3 million people 
from Scotland, which provides strong support for the association 
between ChAdOx1nCoV-19 vaccine and Guillain–Barré syndrome. 
The study design and sensitivity analyses addressed some of the key 
issues related to this association, including confounding through 
fixed covariates, seasonality and variable exposures to predisposing 
infections during the pre- and post-vaccination periods. It remains 
unclear why the ChAdOx1nCoV-19 vaccine appears to contribute 
to the pathogenesis of Guillain–Barré syndrome while BNT162b2 
vaccine does not. Further studies are needed to assess whether anti-
bodies against adenovirus vector-based ChAdOx1nCoV-19 can 
cross-react with components of the peripheral nerves. Furthermore, 
we found that Guillain–Barré syndrome and Bell’s palsy co-occur in 
those who received the ChAdOx1nCoV-19 vaccine. Clinically, this 
is likely to represent a variant of Guillain–Barré syndrome, in line 
with the emerging case reports of Guillain–Barré syndrome variants 
with facial weakness after the ChAdOx1nCoV-19 vaccine16,17.
In those who received the BNT162b2 vaccine, we estimated 60 
excess cases of hemorrhagic strokes per 10 million exposed in the 
28 days after vaccination. We did not observe an increased risk of 
hemorrhagic stroke in those who received the ChAdOx1nCoV-19 
vaccine. However, the magnitude of this association between 
BNT162b2 and hemorrhagic stroke was reduced in sensitivity anal-
yses that accounted for fatal events. Intriguingly, the increased risk 
of hemorrhagic stroke associated with BNT162b2 was substantially 
higher in female participants than in male participants, suggesting 
that sex may further modify this risk. The mechanisms underly-
ing this disparity in risk between the two vaccines is not clear but 
several reports have suggested an increased risk of immune throm-
bocytopenic purpura in individuals receiving mRNA vaccines18,19, 
which in turn could contribute to major bleeding events. It is worth 
highlighting that the association between the BNT162b2 vaccine 
and hemorrhagic stroke was not replicated using Scottish data in 
the context of a low number of events, and thus further validation of 
this finding is warranted.
In line with previous surveillance studies14,15, we identified that 
all investigated neurological conditions were linked to SARS-CoV-2 
infection itself. Specifically, we noted an excess of inflammatory 
disorders including encephalitis meningitis and myelitis (123 
excess cases per 10 million exposed), myasthenic disorders (163 
excess cases per 10 million exposed) and Guillain–Barré syndrome 
(145 excess cases per 10 million exposed) in the 1–28 days period 
after a positive test. Our post-hoc analysis restricting to those who 
had a positive test prior to vaccination did not change the results. 
Unfortunately, the number of people with a SARS-CoV-2-positive 
test after vaccination was too small to evaluate the risk of neuro-
logical complications in this group. The highest IRRs for these 
neurological outcomes were typically seen on day 0 (the day of the 
positive test). We included day 0 on its own as a risk period because 
hospital admission can trigger SARS-CoV-2 testing; however, this 
could overestimate or underestimate the overall risks associated 
with infection. The number of people infected in Scotland (3%) 
was much smaller than in England (~6%), reflecting differences in 
infection rates and containment measures in the two countries.
Findings from this study have clear clinical and public health 
implications. Crucially, we found that the risk of neurological com-
plications from infection was substantially higher than the risk of 
adverse events from vaccinations in our population (for example, 145 
excess cases versus 38 excess cases of Guillain–Barré syndrome per 
10 million exposed in those who had a positive SARS-CoV-2 test and 
ChAdOx1nCoV-19 vaccine, respectively). This will need ongoing 
analysis and monitoring as younger people are vaccinated. Clearly, 
neurological complications from vaccination and infection reported 
in this study are rare. However, these rare complications can cause 
lifelong disability requiring long-term care. Collectively, these results 
provide timely and valuable information that can help to inform 
clinical decision making, including facilitating earlier diagnosis, as 
well as resource allocation for health-care provision. This may be 
particularly relevant for intensive care unit resource planning, given 
the potential need for prolonged admission to intensive care units 
for a proportion of patients with Guillain–Barré syndrome20.
This study had several strengths. First, the United Kingdom 
was an ideal place to carry out this study given that both the 
ChAdOx1nCoV-19 and BNT162b2 vaccines have been rolled out 
at speed and scale. Second, this was a population-based study of 
prospectively recorded medical data and it avoided the recall and 
selection biases linked to case reports. Third, the large sample size 
provided sufficient power to investigate these rare neurological out-
comes that could not be assessed through clinical trials. Fourth, the 
SCCS study design (Fig. 2) removes potential confounding from 
fixed characteristics, and the breakdown of the study period into 
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weekly blocks accounted for temporal confounding. Last, the key 
finding that the ChAdOx1nCoV-19 vaccine was associated with an 
increased risk of subsequent Guillain–Barré syndrome was inde-
pendently replicated using Scottish national data.
There were several limitations to this study. We examined the 
risks associated only with the first vaccine dose because the data 
on outcomes following second doses were limited at the time of 
this study. Furthermore, it was not possible to distinguish between 
Guillain–Barré syndrome variants including Miller Fisher syn-
drome in view of the coding used in the Hospital Episode Statistics 
database. Also, given that we investigated only hospital admissions 
and mortality, a proportion of patients with milder neurologi-
cal disease may not have been included and the overall burden of 
neurological adverse events from vaccination and infection could 
be underestimated. Some hospital admissions for myasthenic dis-
orders could represent exacerbations of previously well-controlled 
myasthenic illness given that we excluded only those with a prior 
hospital contact for these neurological conditions in the preceding 
2 years. The Scottish replication cohort was smaller than the study 
cohort, which meant that estimates were less precise and we did not 
have sufficient statistical power to replicate findings with smaller 
effect sizes.
In summary, this population-based study identifies and quan-
tifies several rare neurological adverse events that are specific 
to the ChAdOx1nCoV-19 and BNT162b2 vaccines, as well as 
SARS-CoV-2 infection. We believe that these findings are likely 
to be of relevance to other countries using these vaccines and it 
would be useful to replicate these results in similarly large datasets 
internationally. Clinicians should be aware of these rare complica-
tions, and the findings from this study will be paramount to policy 
makers in risk–benefit evaluations and health-care resource alloca-
tion. Importantly, the risks of adverse neurological events follow-
ing SARS-CoV-2 infection are much greater than those associated 
with vaccinations, highlighting the benefits of ongoing vaccination 
programs.
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Methods
Ethics approval. National Health Service Research Ethics Committee (NHS REC) 
approval was obtained from East Midlands-Derby Research Ethics Committee 
[reference 04/03/2021].
Data. We used the NIMS Database of COVID-19 vaccination to identify vaccine 
exposure. This includes vaccine type, date and doses for all people vaccinated in 
England. National SARS-CoV-2 infection data were obtained from Public Health 
England (PHE).
This study used International Classification of Diseases 10 (ICD-10) codes to 
define neurological outcomes of interest (Supplementary Table 8). The diagnoses 
were extracted from Hospital Episode Statistics (HES), which is a database 
containing details of all admissions to National Health System (NHS) hospitals in 
England
We linked NIMS, at the individual level, to national data for mortality (Office 
for National Statistics, ONS), hospital admissions (HES) and SARS-CoV-2 infection 
data (PHE). This information is now summarized in Extended Data Fig. 3.
Study design. The SCCS design was originally developed to examine vaccine 
safety14,15. The method includes only individuals who have had the outcome of 
interest (cases) and compares the incidence rate (in each case) of the outcome of 
interest during a time-limited exposed period (for example, immediately after 
vaccination) with rates during unexposed periods (that is, baseline). A relative 
incidence greater than 1 indicates an increased risk after vaccination or a positive 
SARS-CoV-2 test. Given that the analyses are conditional on each case, any fixed 
characteristics during the study period, such as sex, ethnicity or chronic conditions, 
are inherently controlled for. Any time-varying factors, such as seasonal variation, 
need to be adjusted for in the analyses.
A flowchart showing how each dataset used for the SCCS analysis of each 
outcome was created is presented in Extended Data Fig. 3.
Study period and population. We examined the associations between 
ChAdOx1nCoV-19 or BNT162b2 vaccines and neurological complications 
during the ongoing COVID-19 vaccination program in England (commenced on 
8 December 2020). We also investigated the association between a SARS-CoV-
2-positive test and the neurological diseases of interest in these vaccinated 
individuals. Separate analyses were carried out for each neurological outcome of 
interest. People were considered eligible for inclusion in each study cohort if they 
had received at least one vaccine dose, were at least 16 years old, and were admitted 
to hospital or died from the outcome of interest between 1 December 2020 and 31 
May 2021 (last data update). Patients were followed up from the start (1 December 
2020) to the earliest of either the end of the study period (31 May 2021), the date 
of second dose or when they died. Only the first outcome event during the study 
period was included. Patients with a hospital admission for the same outcome 
in the 2 years prior to the start of the study period were excluded. We excluded 
patients who received the mRNA-1273 (Moderna) vaccine given that the number 
of these patients was too small for meaningful analysis.
Outcomes. The neurological outcomes in this study were selected a priori based 
on a literature search for any reports of emerging neurological complications from 
SARS-CoV-2 infection and vaccination. These included acute CNS demyelinating 
events, encephalitis meningitis and myelitis (excluding encephalopathy), Guillain–
Barré syndrome (encapsulating all Guillain–Barré syndrome variants including 
Miller Fisher syndrome), Bell’s palsy, myasthenic disorders, hemorrhagic stroke 
and subarachnoid hemorrhage. Other outcomes, such as peripheral neuropathies, 
were excluded because these conditions were unlikely to result in hospital 
admission (particularly within the 28 day risk period in this study). We used the 
ICD-10 codes to define each outcome, as listed in Supplementary Table 8. The 
outcomes were identified as the first hospital admission due to the event of interest 
or as a cause of death recorded on the death certificate with the event.
Exposures. The exposure variables were a first dose of the ChAdOx1nCoV-19 or 
BNT162b2 vaccines and first infection with SARS-CoV-2, defined as a positive 
COVID-19 polymerase chain reaction (PCR) test during the study period 
(either before or after vaccination). For all outcomes we defined the exposure 
risk intervals as the following pre-specified time periods: 0, 1–7, 8–14, 15–21 
and 22–28 days after each exposure date, under the assumption that the adverse 
events under consideration are unlikely to be related to exposure beyond 28 days 
after the exposure. We assumed that patients who experienced an outcome before 
vaccination would probably delay vaccination until symptoms had improved. 
Therefore we included a pre-risk period in the analyses, defined as the 1–28 days 
immediately before the vaccination or SARS-CoV-2 test. The baseline period was 
then defined as extending from 1 December 2020 to 29 days before the exposure 
date, and from 29 days after the exposure date to 31 May 2021 or the censored 
date, if earlier. Hospital admissions for the events of interest can trigger COVID-19 
testing. Such events may well be caused by SARS-CoV-2 infection, but the reverse 
causality involved in their detection induces bias. To reduce the bias, which could 
overestimate or underestimate the effect of infection, we allocated day 0 to a risk 
period on its own.
Seasonality and COVID-19 pandemic period. Some outcomes of interest have 
seasonal variation: for example, Guillain–Barré syndrome is more common in 
the winter months21. Moreover, hospital admissions were probably influenced 
by the pressure on the health systems due to COVID-19, which was not uniform 
during the pandemic period. To allow for these underlying seasonal effects, we 
split the observational study period into weeks and adjusted for week as a factor 
variable in the statistical models. In doing so, we estimated the relative incidence 
in exposure periods up to 28 days after vaccination compared with the unexposed 
periods, adjusted for underlying seasonality, which accounted for changes in 
hospital admission rates caused by the pandemic. If an exposure period is long in 
relation to the observation period, it might be impossible to distinguish between 
seasonal variation and vaccine effects. However, given that the exposure period 
was relatively short (28 days), this was unlikely to happen given that after 28 days 
a vaccinated patient returns to the baseline period, ensuring that in each interval 
both exposed and unexposed cases appear (Extended Data Fig. 4).
Statistical analysis. We described the characteristics of each cohort (vaccinated 
patients with the outcomes of interest) in terms of age and sex. The SCCS models 
were fitted using a conditional Poisson regression model with an offset for the 
length of the risk period. IRRs, the rates of hospital admission or death due to each 
outcome of interest in risk periods relative to baseline periods, and their 95% CI 
were estimated using the SCCS model adjusted for week number as time-varying 
covariates. Exposure terms for both vaccines and for infection with SARS-CoV-2 
were included in the same model.
We conducted sensitivity analyses to assess the robustness of results to 
assumptions such as that the occurrence of an outcome event did not influence 
the probability of subsequent exposures, by (1) excluding those who died from 
the outcome and (2) restricting analysis to the post-vaccination period, without 
censoring at death due to the outcome; to assess potential reporting delays in the 
data by (3) restricting the study period until 1 May 2021; and to test the choice 
of the follow-up period by (4) restricting analysis to patients who received only 
one vaccine dose and (5) censoring at 12 weeks after vaccination or at the date of 
a second dose if earlier. To test our assumption that events after 28 days are not 
related to the vaccines, we did an additional analysis with a 35 day risk period after 
exposure.
To further validate the estimated IRR associated with a positive SARS-CoV-2 
test, we also restricted the analyses to only patients who had a positive 
SARS-CoV-2 test before vaccination.
Stata version 17 was used for these analyses.
Absolute measures of effect. Absolute risk differences cannot be obtained using 
the SCCS methodology. We supplemented our estimates of IRRs with measures 
of the effect of each exposure in absolute terms, using a method22 developed to 
estimate the number of exposures needed to produce one excess adverse outcome 
and the excess number of events per 10 million exposed for each outcome.
Interactions with age and sex. We investigated whether the association between 
vaccine exposures and outcomes is sex or age dependent by including, in the 
analysis, interaction terms between these covariates and the exposures. We used 
the likelihood ratio test to assess the interaction terms. We present results in 
separate subgroups when an interaction was significant.
Negative and positive control. We examined the association of exposures 
with celiac disease as a negative control outcome23, which is assumed not to be 
associated with exposure to vaccination or SARS-CoV-2 infection; and with 
anaphylaxis as a positive control outcome given that it could occur shortly after 
vaccination with either vaccine24.
Assessing the SCCS assumptions. To further assess the assumptions of the SCCS 
and our modeling choices, we visually examined the data. We plotted a histogram 
of the number of occurrences of an event by time prior to or since vaccination 
for each outcome to assess the possibility that a hospital admission for that 
event might affect subsequent vaccination (Extended Data Fig. 5). We plotted a 
histogram of the time from the event to the actual end of observation in censored 
and uncensored cases to assess whether event-dependent observation periods may 
be a problem for the analysis (Extended Data Fig. 6).
Event-dependent exposures. Extended Data Fig. 5 shows the number of occurrences 
of an event by time before or since vaccination. We notice that there is a decrease 
in the 28 days immediately before vaccination, indicating that occurrence of an 
event might have reduced the likelihood of vaccination. This pattern is similar for 
most of the outcomes and for both vaccines. Therefore, we have added the pre-risk 
period of 28 days.
Event-dependent observation periods. Extended Data Fig. 6 shows the frequency of 
days from the event to the actual end of observation in censored and uncensored 
cases. A spike close to zero is apparent in the censored data histogram for 
hemorrhagic stroke and subarachnoid hemorrhage. This indicates the presence of 
event-dependent observation periods (censoring on death date due to outcome), 
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which we tested further with sensitivity analyses 1 and 2. These additional analyses 
were in agreement with the main analysis, suggesting that there should be little 
concern for these outcomes.
Replication using national Scottish data. To assess the robustness of the findings, 
we carried out an independent replication of the risks of neurological outcomes 
in vaccine recipients using a similar SCCS design. NHS Scotland provides 
comprehensive health care that is free at the point of care for all residents, with 
a base population that includes 5.4 million residents (~95% of the population) 
registered with a general medical practice in Scotland. We used deterministic 
linkage (based on the Community Health Index) to link vaccination information 
(extracted from general medical practice records and the Turas Vaccination 
Management Tool) and hospitalization records (from the Scottish Morbidity 
Records 01), mortality data (from National Records of Scotland) and SARS-Cov-2 
infection data (from Electronic Communication of Surveillance in Scotland).
We classified exposures and outcomes in a similar way to the main analysis. An 
individual was defined as exposed to either the ChAdOx1nCoV-19 or BNT162b2 
vaccine on the date that they received their first dose between 8 December 2020 
and 31 May 2021. We defined outcomes of interest using the same ICD-10 codes 
as for the main analysis. We excluded patients who experienced the outcome in the 
2 years prior to the study start date and excluded patients under 16 years of age. We 
fitted conditional Poisson regression models with an offset for the length of the risk 
period and adjusted for the weekly time period as a time-varying covariate. The 
control (baseline) period was the period from 1 December 2020 to 29 days before 
vaccination, allowing for a 28 day clearance (that is, pre-risk) period, and from 
29 days after the exposure date to 31 May 2021 or the censored date, if earlier. We 
also stratified the post-vaccination follow-up period using the same time periods as 
the analysis in England when the number of events allowed. We also repeated the 
analysis by replacing vaccination with SARS-CoV-2 infection, which was defined 
as a positive PCR test within the study period. Given the smaller population size 
of Scotland, we focused on assessing the consistency of the point estimates of 
associations observed in the main analyses.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
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Extended Data Fig. 1 | Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to 
ChAdOx1nCoV-19 vaccine. Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure 
to ChAdOx1nCoV-19 vaccine, adjusted for calendar time from 1 December 2020 to 31 May 2021 computed using a population of size n = 32,553,534 
vaccinated individuals. Comparisons between different sensitivity analyses (cells with < 5 are suppressed). Horizontal bold line indicates 1.
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Extended Data Fig. 2 | Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to 
BNt162b2 mRNA vaccine. Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure 
to BNT162b2 mRNA vaccine, adjusted for calendar time from 1 December 2020 to 31 May 2021 computed using a population of size n = 32,553,534 
vaccinated individuals. Comparisons between different sensitivity analyses (cells with < 5 are suppressed). Horizontal bold line indicates 1.
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Extended Data Fig. 3 | Data flow chart. Flowchart of data used in this study showing how data from National Immunisation Management System (NIMS), 
Second Generation Surveillance System (SGSS), Hospital Episode Statistics (HES) and Office of National Statistic (ONS) were used to obtain information 
about vaccinations, SARS-CoV-2 test results, and hospital admissions for neurological outcomes and deaths, respectively.
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Extended Data Fig. 4 | Number of hospital admissions or deaths for each outcome in the baseline and in the exposed set by week. Number of hospital 
admissions or deaths for each outcome in the baseline and in the exposed set by week from 1 December 2020 to 31 May 2021 (n = 32,553,534).
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Extended Data Fig. 5 | Number of hospital admissions or deaths for each outcome prior and post each vaccine. Number of hospital admissions or deaths 
for each outcome prior and post each vaccine from 1 December 2020 to 31 May 2021 (n = 32,553,534). Red line: vaccine date; green line: 28 days prior 
vaccine; black line: 28 days post vaccine.
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Extended Data Fig. 6 | time between end of study or censored date and date of hospital admission or deaths for each outcome. Time between end of 
study or censored date and date of hospital admission or deaths for each outcome from 1 December 2020 to 31 May 2021 (n = 32,553,534).
NAtuRe MeDICINe | www.nature.com/naturemedicine


